|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2011-3-28
|
|
pubmed:abstractText |
• To explore the efficacy and safety of testosterone undecanoate (TU) (Nebido®; Bayer Schering Pharma AG, Berlin, Germany) in patients with bilateral germ cell testicular cancer (GCTC) who have switched androgen substitution from testosterone enanthate (Primoteston Depot®, Bayer Schering Pharma AG).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1464-410X
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
© 2010 THE AUTHORS. BJU INTERNATIONAL © 2010 BJU INTERNATIONAL.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
107
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1080-7
|
|
pubmed:meshHeading |
pubmed-meshheading:20825398-Adult,
pubmed-meshheading:20825398-Androgens,
pubmed-meshheading:20825398-Epidemiologic Methods,
pubmed-meshheading:20825398-Humans,
pubmed-meshheading:20825398-Hypogonadism,
pubmed-meshheading:20825398-Injections, Intramuscular,
pubmed-meshheading:20825398-Male,
pubmed-meshheading:20825398-Middle Aged,
pubmed-meshheading:20825398-Neoplasms, Germ Cell and Embryonal,
pubmed-meshheading:20825398-Orchiectomy,
pubmed-meshheading:20825398-Testicular Neoplasms,
pubmed-meshheading:20825398-Testosterone,
pubmed-meshheading:20825398-Treatment Outcome
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Androgen substitution with testosterone undecanoate in survivors of bilateral testicular cancer requires individually-adjusted injection intervals.
|
|
pubmed:affiliation |
Department of Oncology, Oslo University Hospital and University of Oslo, Norway. sigmund.brabrand@oslouniversitetssykehus.no
|
|
pubmed:publicationType |
Journal Article
|
